Peter G Rose

Summary

Affiliation: Cleveland Clinic Foundation
Country: USA

Publications

  1. doi request reprint Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study
    Peter G Rose
    Dept of Ob Gyn, Cleveland Clinic, Cleveland, OH 44109, United States Electronic address
    Gynecol Oncol 143:511-515. 2016
  2. pmc Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized T
    Peter G Rose
    Peter G Rose, Cleveland Clinic Foundation and Case Western Reserve University, Cleveland, OH James Java, Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, NY Charles W Whitney, Christiana Gynecologic Oncology, Apex Medical Center, Newark, DE Frederick B Stehman, Mel and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN Rachelle Lanciano, Delaware County Regional Cancer Center, Drexel Hill, PA Gillian M Thomas, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada and Paul A DiSilvestro, Women and Infants Hospital, Brown University, Providence, RI
    J Clin Oncol 33:2136-42. 2015
  3. pmc Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in gynecologic oncology group trials of cisplatin-based chemoradiation
    Peter G Rose
    Gynecologic Oncology, Department of Obstetrics and Gynecology, Cleveland Clinic Foundation and Case Western Reserve University, Cleveland, OH 44195, United States Electronic address
    Gynecol Oncol 135:208-12. 2014
  4. pmc Pegylated liposomal doxorubicin in ovarian cancer
    Andrew E Green
    Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cleveland Clinic, Cleveland, OH 44195, USA
    Int J Nanomedicine 1:229-39. 2006
  5. doi request reprint Evidence of extended (>7 years) activity of bevacizumab and metronomic cyclophosphamide in a patient with platinum-resistant low-grade serous ovarian carcinoma
    Peter G Rose
    Division of Gynecologic Oncology, Cleveland Clinic Health System, Ohio 44195, USA
    Anticancer Drugs 24:986-8. 2013
  6. pmc A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: a gynecologic oncology group study
    Peter G Rose
    Case Western Reserve University, Cleveland, OH 44195, USA
    Gynecol Oncol 125:158-62. 2012
  7. ncbi request reprint Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group
    Peter G Rose
    Division of Gynecologic Oncology, Case Western Reserve University, Department of Obstetrics and Gynecology, Cleveland Clinic Foundation, A81, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Gynecol Oncol 104:114-9. 2007
  8. ncbi request reprint A phase I/II trial of weekly topotecan and carboplatin in potentially platinum-sensitive relapsed ovarian and peritoneal carcinoma
    Peter G Rose
    MetroHealth Medical Center, Cleveland, Ohio 44195, USA
    Gynecol Oncol 99:714-9. 2005
  9. ncbi request reprint Sequential prolonged oral topotecan and prolonged oral etoposide as second-line therapy in ovarian or peritoneal carcinoma: a phase I Gynecologic Oncology Group study
    Peter G Rose
    Division of Gynecologic Oncology, Case Western Reserve University, and MetroHealth Medical Center, Cleveland, OH, USA
    Gynecol Oncol 102:236-9. 2006
  10. ncbi request reprint Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer
    Peter G Rose
    Cleveland Clinic Taussig Cancer Center, 9500 Euclid Avenue, A 81, Cleveland, Ohio 44195, USA
    Oncologist 10:205-14. 2005

Detail Information

Publications91

  1. doi request reprint Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study
    Peter G Rose
    Dept of Ob Gyn, Cleveland Clinic, Cleveland, OH 44109, United States Electronic address
    Gynecol Oncol 143:511-515. 2016
    ..The current analysis was undertaken to evaluate the impact of disease findings at SCS on progression-free survival (PFS) and overall survival (OS)...
  2. pmc Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized T
    Peter G Rose
    Peter G Rose, Cleveland Clinic Foundation and Case Western Reserve University, Cleveland, OH James Java, Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, NY Charles W Whitney, Christiana Gynecologic Oncology, Apex Medical Center, Newark, DE Frederick B Stehman, Mel and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN Rachelle Lanciano, Delaware County Regional Cancer Center, Drexel Hill, PA Gillian M Thomas, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada and Paul A DiSilvestro, Women and Infants Hospital, Brown University, Providence, RI
    J Clin Oncol 33:2136-42. 2015
    ..To evaluate the prognostic factors in locally advanced cervical cancer limited to the pelvis and develop nomograms for 2-year progression-free survival (PFS), 5-year overall survival (OS), and pelvic recurrence...
  3. pmc Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in gynecologic oncology group trials of cisplatin-based chemoradiation
    Peter G Rose
    Gynecologic Oncology, Department of Obstetrics and Gynecology, Cleveland Clinic Foundation and Case Western Reserve University, Cleveland, OH 44195, United States Electronic address
    Gynecol Oncol 135:208-12. 2014
    ..The current study sought to evaluate impact of adeno- and adenosquamous histology in the randomized trials of primary cisplatin-based chemoradiation for locally advanced cervical cancer...
  4. pmc Pegylated liposomal doxorubicin in ovarian cancer
    Andrew E Green
    Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cleveland Clinic, Cleveland, OH 44195, USA
    Int J Nanomedicine 1:229-39. 2006
    ....
  5. doi request reprint Evidence of extended (>7 years) activity of bevacizumab and metronomic cyclophosphamide in a patient with platinum-resistant low-grade serous ovarian carcinoma
    Peter G Rose
    Division of Gynecologic Oncology, Cleveland Clinic Health System, Ohio 44195, USA
    Anticancer Drugs 24:986-8. 2013
    ..This case report adds to the growing literature regarding the use of bevacizumab in low-grade serous ovarian carcinoma...
  6. pmc A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: a gynecologic oncology group study
    Peter G Rose
    Case Western Reserve University, Cleveland, OH 44195, USA
    Gynecol Oncol 125:158-62. 2012
    ..To determine the maximum tolerated dose (MTD) and acute dose-limiting toxicities (DLT) of intravenous topotecan administered with weekly cisplatin during pelvic radiation therapy in patients with locally advanced cervical cancer...
  7. ncbi request reprint Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group
    Peter G Rose
    Division of Gynecologic Oncology, Case Western Reserve University, Department of Obstetrics and Gynecology, Cleveland Clinic Foundation, A81, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Gynecol Oncol 104:114-9. 2007
    ....
  8. ncbi request reprint A phase I/II trial of weekly topotecan and carboplatin in potentially platinum-sensitive relapsed ovarian and peritoneal carcinoma
    Peter G Rose
    MetroHealth Medical Center, Cleveland, Ohio 44195, USA
    Gynecol Oncol 99:714-9. 2005
    ..This phase I/II trial combined weekly topotecan, which is less myelosuppressive than the standard 5-day regimen, with carboplatin in patients with potentially platinum-sensitive relapsed ovarian or peritoneal carcinoma (PS-OVCa/PCa)...
  9. ncbi request reprint Sequential prolonged oral topotecan and prolonged oral etoposide as second-line therapy in ovarian or peritoneal carcinoma: a phase I Gynecologic Oncology Group study
    Peter G Rose
    Division of Gynecologic Oncology, Case Western Reserve University, and MetroHealth Medical Center, Cleveland, OH, USA
    Gynecol Oncol 102:236-9. 2006
    ..A phase I study was conducted in previously treated ovarian or peritoneal carcinoma to determine the tolerability (maximum number of days) of sequential oral topotecan and oral etoposide...
  10. ncbi request reprint Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer
    Peter G Rose
    Cleveland Clinic Taussig Cancer Center, 9500 Euclid Avenue, A 81, Cleveland, Ohio 44195, USA
    Oncologist 10:205-14. 2005
    ....
  11. doi request reprint A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer
    Peter G Rose
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cleveland Clinic Foundation Case Western Reserve University, Cleveland, OH 44195, USA
    Am J Clin Oncol 31:476-80. 2008
    ....
  12. ncbi request reprint A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma
    Peter G Rose
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, MetroHealth Medical Center, Case Western Reserve University, 2500 MetroHealth Drive, Cleveland, OH 44109, USA
    Gynecol Oncol 96:296-300. 2005
    ..We studied weekly paclitaxel and 3-week carboplatin in potentially platinum-sensitive recurrent ovarian and peritoneal carcinoma...
  13. doi request reprint Impact of hydronephrosis on outcome of stage IIIB cervical cancer patients with disease limited to the pelvis, treated with radiation and concurrent chemotherapy: a Gynecologic Oncology Group study
    Peter G Rose
    Cleveland Clinic Foundation and Case Western Reserve University, Cleveland, OH 44195, USA
    Gynecol Oncol 117:270-5. 2010
    ..To estimate the significance of hydronephrosis and impact of ureteral obstruction relief on outcome in patients with stage IIIB cervical cancer treated with radiation and concurrent chemotherapy...
  14. doi request reprint Outcome of stage IVA cervical cancer patients with disease limited to the pelvis in the era of chemoradiation: a Gynecologic Oncology Group study
    Peter G Rose
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cleveland Clinic Foundation and Case Western Reserve University, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Gynecol Oncol 121:542-5. 2011
    ..To evaluate the outcome of stage IVA cervical cancer treated with radiation and concurrent cisplatin-based chemotherapy...
  15. ncbi request reprint Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group
    Peter G Rose
    Division of Gynecologic Oncology, Case Western Reserve University, Cleveland, OH 44106, USA
    Gynecol Oncol 102:210-3. 2006
    ..To determine the level of activity and potential for use in future combinations, a phase II trial of pegylated liposomal doxorubicin as second-line therapy in advanced and recurrent cervical cancer was performed...
  16. doi request reprint An open-label, single-arm Phase II study of intravenous weekly (Days 1 and 8) topotecan in combination with carboplatin (Day 1) every 21 days as second-line therapy in patients with platinum-sensitive relapsed ovarian cancer
    Peter G Rose
    Division of Gynecologic Oncology, Cleveland Clinic and MetroHealth Medical Center, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Gynecol Oncol 120:38-42. 2011
    ..To evaluate clinical activity of weekly topotecan plus carboplatin in patients with platinum-sensitive recurrent ovarian, fallopian tube, or peritoneal carcinoma...
  17. ncbi request reprint Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study
    William E Winter
    Department of Obstetrics and Gynecology, Gynecologic Oncology, Brooke Army Medical Center, Ft Sam Houston, TX, USA
    J Clin Oncol 26:83-9. 2008
    ..To identify factors predictive of poor prognosis in a similarly treated population of women with stage IV epithelial ovarian cancer (EOC)...
  18. doi request reprint An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC)
    Amanda Nickles Fader
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Cleveland Clinic, Cleveland, OH, USA
    Gynecol Oncol 115:244-8. 2009
    ..However, clinicopathologic risk factors for recurrence are not well understood. This study was undertaken to define the prognostic factors for recurrence and survival in patients with early-stage UPSC...
  19. pmc Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials
    Vivian E von Gruenigen
    Department of Reproductive Biology, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, Ohio 44106, USA
    Cancer 115:4857-64. 2009
    ..The objective of this study was to assess which quality-of-life (QOL) line items on the Functional Assessment of Cancer Therapy-Ovarian (FACT-O) were associated with low QOL in women who were receiving chemotherapy for ovarian cancer...
  20. ncbi request reprint Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity
    Peter G Rose
    Case Western Reserve University, Ireland Cancer Center, Cleveland, OH 44106, USA
    Gynecol Oncol 89:429-33. 2003
    ....
  21. ncbi request reprint A phase I study of gemcitabine followed by cisplatin concurrent with whole pelvic radiation therapy in locally advanced cervical cancer: a Gynecologic Oncology Group study
    Peter G Rose
    Case Western Reserve University and Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Gynecol Oncol 107:274-9. 2007
    ..To determine the maximum tolerated dose (MTD) of gemcitabine followed by cisplatin that can be administered weekly during pelvic radiation therapy in patients with locally advanced cervical cancer...
  22. doi request reprint Retrospective analysis of concomitant Cisplatin during radiation in patients aged 55 years or older for treatment of advanced cervical cancer: a gynecologic oncology group study
    Charles Kunos
    Department of Radiation Oncology, Case Comprehensive Cancer Center and University Hospitals of Cleveland Case Medical Center, Cleveland, Ohio, USA
    Int J Gynecol Cancer 19:1258-63. 2009
    ....
  23. pmc Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group
    Mark A Morgan
    Section of Gynecologic Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Gynecol Oncol 110:329-35. 2008
    ....
  24. pmc The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study
    Kristin K Zorn
    Division of Gynecologic Oncology, Magee Womens Hospital of the University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
    Cancer 115:1028-35. 2009
    ..The objective of the current study was to determine the prognostic significance of a pretreatment serum CA 125 level in patients with advanced epithelial ovarian carcinoma (EOC) who received treatment with a standard chemotherapy regimen...
  25. doi request reprint Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes
    Amanda Nickles Fader
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk A 81, Cleveland, Ohio 44195, USA
    Gynecol Oncol 112:558-62. 2009
    ..To determine recurrence patterns and survival outcomes of stage II uterine papillary serous carcinoma (UPSC) patients treated by various modalities with an emphasis on carboplatin/paclitaxel-based chemotherapy (CT)+/-radiotherapy (RT)...
  26. doi request reprint A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study
    D Scott McMeekin
    Department of Obstetrics and Gynecology, Gynecologic Oncology Section, University of Oklahoma, Oklahoma City, OK 73104, USA
    Gynecol Oncol 127:356-61. 2012
    ....
  27. ncbi request reprint Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study
    William E Winter
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brooke Army Medical Center, Ft Sam
    J Clin Oncol 25:3621-7. 2007
    ..The purpose of this study was to identify factors predictive of poor prognosis in a similarly treated population of women with advanced EOC...
  28. ncbi request reprint Serous fallopian tube carcinoma: a retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary
    Kathleen N Moore
    University of Oklahoma, Division of Gynecologic Oncology, 920 SL Young Blvd, Oklahoma City, OK 73104, USA
    Gynecol Oncol 107:398-403. 2007
    ..Primary carcinoma of the fallopian tube (PCFT) is a rare malignancy comprising 1% of genital tract cancers. We sought to compare survival trends between PCFT and ovarian carcinoma (OC) patients (pts) in a matched, case-control comparison...
  29. ncbi request reprint A phase I trial of prolonged oral etoposide and liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study
    Peter G Rose
    Division of Gynecologic Oncology, Case Western Reserve University, Cleveland, Ohio 44109, USA
    Gynecol Oncol 85:136-9. 2002
    ..In an effort to explore second-line therapy in ovarian, peritoneal, and tubal carcinoma, a phase I trial combining prolonged oral etoposide and liposomal doxorubicin was conducted by the Gynecologic Oncology Group...
  30. pmc A comparison of quality-of-life domains and clinical factors in ovarian cancer patients: a Gynecologic Oncology Group study
    Vivian E von Gruenigen
    Department of Reproductive Biology, University Hospitals Case Medical Center, Cleveland, Ohio 44106, USA
    J Pain Symptom Manage 39:839-46. 2010
    ..Women diagnosed with ovarian cancer are at risk for reduced quality of life (QOL). It is imperative to further define these declines to interpret treatment outcomes and design appropriate clinical interventions...
  31. ncbi request reprint Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma
    Peter G Rose
    Case Western Reserve University and Ireland Cancer Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University Hospitals of Cleveland, Ohio 44106, USA
    Gynecol Oncol 88:17-21. 2003
    ..We evaluated the cisplatin and gemcitabine regimen in patients with platinum refractory and multidrug refractory ovarian and peritoneal carcinoma...
  32. doi request reprint Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: a Gynecologic Oncology Group study
    Peter G Rose
    Cleveland Clinic Foundation, Case Western Reserve University, Cleveland, OH 44195, USA
    Gynecol Oncol 117:324-9. 2010
    ....
  33. doi request reprint Concurrent cisplatin-based chemoradiation International Federation of Gynecology and Obstetrics stage IB2 cervical carcinoma
    Behiye P C Goksedef
    Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cleveland Clinic, Cleveland, OH 44195, USA
    Am J Obstet Gynecol 200:175.e1-5. 2009
    ..The objective of the study was to assess the effectiveness of primary chemoradiation for stage IB(2) cervical carcinoma...
  34. ncbi request reprint Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study
    Peter G Rose
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Case Western Reserve University and Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    J Clin Oncol 25:2804-10. 2007
    ....
  35. pmc Which clinical/pathologic factors matter in the era of chemoradiation as treatment for locally advanced cervical carcinoma? Analysis of two Gynecologic Oncology Group (GOG) trials
    Bradley J Monk
    Department of Ob Gyn, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, and Department of Radiation Oncology, Delaware County Memorial Hospital, Drexel Hill, PA 19026, USA
    Gynecol Oncol 105:427-33. 2007
    ..To explore clinical/pathologic factors associated with prognosis of patients with locally advanced cervical carcinoma treated with weekly cisplatin and pelvic radiation...
  36. pmc CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study
    Chunqiao Tian
    Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, New York, USA
    Cancer 115:1395-403. 2009
    ..There are limited data regarding unique clinical or laboratory features associated with advanced clear cell (CC) and mucinous (MU) epithelial ovarian cancers (EOC), particularly the relationship between CA-125 antigen levels and prognosis...
  37. ncbi request reprint Radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in cervical carcinoma limited to the pelvis: a phase I/II study of the Gynecologic Oncology Group
    Paul A DiSilvestro
    Program in Womens Oncology, Women and Infants Hospital, 101 Dudley Street, Providence, RI 02905, and Division of Gynecologic Oncology, University of Oklahoma, Oklahoma City 73190, USA
    Gynecol Oncol 103:1038-42. 2006
    ..To determine the maximum tolerated dose (MTD) of weekly paclitaxel and cisplatin chemotherapy concurrent with whole pelvic irradiation in women with locally advanced cervical cancer...
  38. doi request reprint Stage I, grade 3 endometrioid adenocarcinoma of the endometrium: an analysis of clinical outcomes and patterns of recurrence
    Nabila Rasool
    Department of Obstetrics and Gynecology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Gynecol Oncol 116:10-4. 2010
    ..To study patterns of recurrence and survival outcomes in patients with surgical stage I, grade 3 endometrioid adenocarcinoma of the endometrium (EA) treated with various treatment modalities...
  39. pmc The impact of combined radiation and chemotherapy on outcome in uterine papillary serous carcinoma compared to chemotherapy alone
    Haider Mahdi
    Gynecologic Oncology Division, Ob Gyn and Women s Health Institute, Cleveland Clinic, Cleveland, OH, USA
    J Gynecol Oncol 27:e19. 2016
    ..To investigate the impact of pelvic radiation on survival in patients with uterine serous carcinoma (USC) who received adjuvant chemotherapy...
  40. doi request reprint A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study
    Kathleen N Moore
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Oklahoma, Oklahoma City, OK 73190, USA
    Gynecol Oncol 127:456-61. 2012
    ..This study assessed the safety of chemoradiation with cetuximab in the treatment of women with newly diagnosed locally advanced cervical cancer...
  41. doi request reprint Surgical versus radiographic determination of para-aortic lymph node metastases before chemoradiation for locally advanced cervical carcinoma: a Gynecologic Oncology Group Study
    Michael A Gold
    Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
    Cancer 112:1954-63. 2008
    ....
  42. ncbi request reprint Secondary surgical cytoreduction for advanced ovarian carcinoma
    Peter G Rose
    Case Western Reserve University and the Division of Gynecologic Oncology, MetroHealth Medical Center, Cleveland, USA
    N Engl J Med 351:2489-97. 2004
    ....
  43. ncbi request reprint Evaluation of concurrent and adjuvant carboplatin with radiation therapy for locally advanced cervical cancer
    Rachel A Dubay
    Department of Obstetrics and Gynecology, MetroHealth Medical Center, Cleveland, OH 44109 1998, USA
    Gynecol Oncol 94:121-4. 2004
    ..To analyze the toxicity profile and long-term outcomes of patients receiving carboplatin with concurrent radiation for locally advanced cervical cancer...
  44. doi request reprint Patterns of recurrence in stage I endometrioid endometrial adenocarcinoma with lymphovascular space invasion
    Fiona Simpkins
    Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Cleveland Clinic Foundation, Cleveland, OH, USA
    Int J Gynecol Cancer 23:98-104. 2013
    ..The objective of this study was to determine the patterns of recurrence of stage IB-IIA endometrioid endometrial adenocarcinoma (EMCA) with lymphovascular invasion (LVSI)...
  45. doi request reprint Endometrial stromal sarcoma: analysis of recurrence following adjuvant treatment
    Tiffany L Beck
    Department of Obstetrics and Gynecology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
    Gynecol Oncol 125:141-4. 2012
    ..The goal of this study was to evaluate the rate of recurrence and the effect of various adjuvant treatment modalities...
  46. pmc Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study
    John Farley
    Department of Obstetrics and Gynecology, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA
    Gynecol Oncol 121:303-8. 2011
    ....
  47. ncbi request reprint Prolonged oral etoposide in recurrent or advanced non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study
    Peter G Rose
    Division of Gynecologic Oncology, Case Western Reserve University, University Hospitals of Cleveland, OH 44106, USA
    Gynecol Oncol 89:267-70. 2003
    ..To evaluate prolonged oral etoposide in nonsquamous cell carcinoma of the cervix, the current phase II trial was conducted...
  48. ncbi request reprint Chemotherapy for newly diagnosed and relapsed advanced ovarian cancer
    Peter G Rose
    MetroHealth Medical Center, Cancer Care Pavilion, Room 2017, 2500 MetroHealth Dr, Cleveland, OH 44109, USA
    Semin Oncol Nurs 19:25-35. 2003
    ..To review chemotherapy options for patients with newly diagnosed or relapsed advanced ovarian cancer...
  49. doi request reprint Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis
    Kathleen N Moore
    Division of Gynecologic Oncology, Stephenson Oklahoma Cancer Center at the University of Oklahoma, 800 NE 10th Street, Oklahoma City, OK 73121, United States Electronic address
    Gynecol Oncol 143:294-301. 2016
    ..To determine the effect of age on completion of and toxicities following treatment of local regionally advanced cervical cancer (LACC) on Gynecologic Oncology Group (GOG) Phase I-III trials...
  50. ncbi request reprint Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening
    Fiona Simpkins
    Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Cleveland Clinic Foundation, 9500 Euclid Avenue, A81, Cleveland, OH, 44195, USA
    Gynecol Oncol 107:118-23. 2007
    ..Since the initial report of this complication, we have limited bevacizumab treatment to patients without: 1) clinical symptoms of bowel obstruction 2) evidence of rectosigmoid involvement on pelvic exam 3) bowel involvement on CT scan...
  51. ncbi request reprint Improvement of paclitaxel-induced neuropathy by substitution of docetaxel for paclitaxel
    Peter G Rose
    Case Western Reserve University and Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cleveland, OH 44109, USA
    Gynecol Oncol 91:423-5. 2003
    ..Although the combination of paclitaxel and carboplatin has a better therapeutic index than the combination of paclitaxel and cisplatin, peripheral neuropathy often occurs and remains the most chronic toxicity of this therapy...
  52. ncbi request reprint Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study
    Katherine Y Look
    Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Gynecol Oncol 92:644-7. 2004
    ..To determine the antitumor activity and toxicity profile of gemcitabine as second-line chemotherapy in patients with recurrent or persistent uterine leiomyosarcoma (LMS)...
  53. ncbi request reprint Management of locally advanced cervical cancer
    Luis A Rojas-Espaillat
    Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Curr Opin Oncol 17:485-92. 2005
    ..This review will critically evaluate the evidence supporting the available treatment modalities for locally advanced cancer of the uterine cervix...
  54. ncbi request reprint CCL2 expression in primary ovarian carcinoma is correlated with chemotherapy response and survival outcomes
    Amanda Nickles Fader
    2Department of Obstetrics and Gynecology, Taussig Cancer Institute, R40, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Anticancer Res 30:4791-8. 2010
    ....
  55. ncbi request reprint Yolk sac tumor of the ovary associated with endometrioid carcinoma with metastasis to the vagina: a case report
    William C McBee
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Case Western Reserve University, MetroHealth Medical Center, 2500 MetroHealth Drive, Cleveland, OH 44109, USA
    Gynecol Oncol 105:244-7. 2007
    ..Mixed yolk sac tumors of the ovary are biologically aggressive even in early stage disease...
  56. doi request reprint Abraxane for the treatment of gynecologic cancer patients with severe hypersensitivity reactions to paclitaxel
    Amanda N Fader
    Department of Gynecology and Obstetrics, The Cleveland Clinic, Cleveland, OH 44195, USA
    Int J Gynecol Cancer 19:1281-3. 2009
    ..Abraxane, a newer, Cremophor-free form of albumin bound paclitaxel has demonstrated an activity and an improved toxicity profile in breast and lung cancers...
  57. ncbi request reprint A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study
    Peter G Rose
    Case Western Reserve University, Division of Gynecologic Oncology, University Hospitals of Cleveland, Cleveland, OH 44106, USA
    Gynecol Oncol 88:130-5. 2003
    ..The Gynecologic Oncology Group (GOG) conducted a study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma to determine its activity, and nature and degree of toxicity, in this cohort of patients...
  58. doi request reprint Prostate-Type Adenocarcinoma in Mature Cystic Ovarian Teratoma
    Jamie Stanhiser
    Department of Obstetrics and Gynecology J S Section of Gynecologic Oncology H M, P G R, Department of Obstetrics and Gynecology Departments of Anatomic Pathology G R, H H, A A R Hematology and Oncology D S, Cleveland Clinic, Cleveland, Ohio
    Int J Gynecol Pathol 35:185-90. 2016
    ....
  59. pmc Lymph node metastasis and pattern of recurrence in clinically early stage endometrial cancer with positive lymphovascular space invasion
    Haider Mahdi
    Division of Gynecologic Oncology, Ob Gyn and Women s Health Institute, Cleveland, OH, USA
    J Gynecol Oncol 26:208-13. 2015
    ..To investigate the rate, predictors of lymph node metastasis (LNM) and pattern of recurrence in clinically early stage endometrial cancer (EC) with positive lymphovascular space invasion (LVSI)...
  60. ncbi request reprint Innovations in the treatment of invasive cervical cancer
    Frederick B Stehman
    Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, Indiana 46202 5274, USA
    Cancer 98:2052-63. 2003
    ..Research advances in both diagnosis and treatment are expected to improve therapy and outcomes...
  61. doi request reprint Abnormal cervical cytology in the diagnosis of uterine papillary serous carcinoma: earlier detection of a poor prognostic cancer subtype?
    Malgorzata E Skaznik-Wikiel
    Obstetrics, Gynecology and Women s Health Institute, Cleveland Clinic, Cleveland, Ohio, USA
    Acta Cytol 55:255-60. 2011
    ..The study objective was to assess the utility of liquid-based cytology (Pap) in the detection of high-grade EC...
  62. doi request reprint Role of gemcitabine in the treatment of ovarian cancer
    Fadi Abushahin
    Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Womens Health (Lond) 3:279-90. 2007
    ..An overview of the literature on the role of gemcitabine in the treatment of epithelial ovarian cancer is also presented...
  63. doi request reprint Activity of Bevacizumab in Patients With Low-Grade Serous Ovarian Carcinoma
    Peter G Rose
    Division of Gynecologic Oncology, Cleveland Clinic Division of Gynecologic Oncology, MetroHealth Medical Center and Department of Molecular Pathology, Cleveland Clinic, Cleveland, OH
    Int J Gynecol Cancer 26:1048-52. 2016
    ..The aim of this study was to evaluate the antitumor activity of bevacizumab in low-grade serous ovarian carcinoma (LGSOC)...
  64. doi request reprint Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study
    Vivian E von Gruenigen
    Division of Gynecologic Oncology, Summa Akron City Hospital, NEOMED, Akron, OH 44304, United States Electronic address
    Gynecol Oncol . 2017
    ....
  65. doi request reprint Outcome of neoadjuvant chemotherapy in BRCA1/2 mutation positive women with advanced-stage Müllerian cancer
    Haider Mahdi
    Division of Gynecologic Oncology, Ob Gyn and Women s Health Institute, Cleveland Clinic, Cleveland, OH, USA Electronic address
    Gynecol Oncol 139:407-12. 2015
    ..To investigate whether patients with germline BRCA1/2 mutations who received neoadjuvant chemotherapy (NAC) for advanced-stage Müllerian cancer (MC) have an improved outcome compared to patients who did not undergo genetic testing...
  66. doi request reprint The Impact of Percent Reduction in CA-125 Levels on Prediction of the Extent of Interval Cytoreduction and Outcome in Patients With Advanced-Stage Cancer of Müllerian Origin Treated With Neoadjuvant Chemotherapy
    Haider Mahdi
    Gynecologic Oncology Division, Ob Gyn and Women s Health Institute, and Quantitative Health Sciences Department, Cleveland Clinic, Cleveland, OH
    Int J Gynecol Cancer 25:823-9. 2015
    ..To investigate the role of CA-125 percent reduction after neoadjuvant chemotherapy in predicting the extent of the interval debulking surgery (IDS) and outcomes in patients with advanced-stage müllerian carcinoma...
  67. doi request reprint A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA)
    Fiona Simpkins
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA, United States
    Gynecol Oncol 136:240-5. 2015
    ..To evaluate the effect of adding bevacizumab to adjuvant paclitaxel and carboplatin and as maintenance on progression-free survival (PFS) in advanced or recurrent endometrial carcinoma (EMCA)...
  68. doi request reprint Racial disparity in 30-day morbidity and mortality after surgery for ovarian cancer
    Haider Mahdi
    Gynecologic Oncology Division, Ob Gyn and Women s Health Institute, Cleveland Clinic, Cleveland, OH and Department of Biostatistics, University of Washington, Seattle, WA
    Int J Gynecol Cancer 25:55-62. 2015
    ..The contribution of immediate postoperative morbidity and mortality to this survival disparity remains unclear. This study aims to examine disparities in postoperative 30-day morbidity and mortality between AA and W women with OC...
  69. ncbi request reprint Role of surgery in ovarian carcinoma
    Amanda Nickles Fader
    Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    J Clin Oncol 25:2873-83. 2007
    ..The indications for fertility-sparing and minimally invasive surgery as well as the current guidelines for prophylactic surgery in high-risk mutation carriers are also discussed...
  70. doi request reprint Trial design for evaluation of novel targeted therapies
    John Farley
    Department of Obstetrics and Gynecology, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA
    Gynecol Oncol 116:173-6. 2010
    ..Alternatives to traditional phase II trial design including alternative end points, randomized designs, biomarkers, and imaging tools are discussed...
  71. ncbi request reprint Surgical staging of gynecologic malignancies: the role of laparoscopy and sentinel node technology
    Robert Kim
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cleveland Clinic Foundation, OH 44195, USA
    Surg Oncol Clin N Am 14:267-88. 2005
  72. ncbi request reprint Docetaxel in ovarian cancer
    Pedro F Escobar
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, A 81, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Expert Opin Pharmacother 6:2719-26. 2005
    ..This article reviews the rationale and indications for the use of docetaxel in ovarian cancer...
  73. ncbi request reprint Symptomatic vaginal bleeding in a postmenopausal woman: a case report of pancreatic adenocarcinoma metastasizing exclusively to the vagina
    Amanda Nickles Fader
    Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, The Cleveland Clinic, Cleveland, OH 44195, USA
    Am J Obstet Gynecol 197:e8-9. 2007
    ..Most cases represent metastases from other pelvic organs or the colon. We present the second case in the literature of a pancreatic adenocarcinoma metastasizing exclusively to the vagina...
  74. doi request reprint Adjuvant vaginal brachytherapy decreases the risk of vaginal recurrence in patients with stage I non-invasive uterine papillary serous carcinoma. A multi-institutional study
    Haider Mahdi
    Gynecologic Oncology Division, Ob Gyn and Women s Health Institute, Cleveland Clinic, Cleveland, OH, USA Electronic address
    Gynecol Oncol 136:529-33. 2015
    ..To investigate the impact of adjuvant vaginal brachytherapy on vaginal recurrence in stage I non-invasive uterine papillary serous carcinoma (UPSC)...
  75. ncbi request reprint Arterial thrombosis in a gynecologic oncology patient: evaluation and management
    Andrew E Green
    Department of Obstetrics and Gynecology, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, Ohio 44106, USA
    Gynecol Oncol 87:228-30. 2002
    ..Presentation, evaluation, and treatment varied considerably in all previous reports of arterial thrombosis associated with any malignancy...
  76. doi request reprint Implementation of tumor testing for lynch syndrome in endometrial cancers at a large academic medical center
    Jessica Moline
    Genomic Medicine Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Gynecol Oncol 130:121-6. 2013
    ..Here we describe our experience implementing a screening program for endometrial cancers...
  77. doi request reprint Fertility-preserving surgical procedures for patients with gynecologic malignancies
    Nabila Rasool
    Department of Obstetrics and Gynecology, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Clin Obstet Gynecol 53:804-14. 2010
    ....
  78. pmc Rationale and design of REWARD (revving-up exercise for sustained weight loss by altering neurological reward and drive): a randomized trial in obese endometrial cancer survivors
    Nora L Nock
    Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH, USA Case Comprehensive Cancer Center, Cleveland, OH, USA Electronic address
    Contemp Clin Trials 39:236-45. 2014
    ....
  79. ncbi request reprint Combined-modality therapy of locally advanced cervical cancer
    Peter G Rose
    Case Western Reserve University and Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, MetroHealth Medical Center, Cleveland, OH 44109, USA
    J Clin Oncol 21:211s-217s. 2003
    ..The potential role of biologic agents in combination with chemoradiotherapy also needs to be examined in locally advanced cervical cancer...
  80. ncbi request reprint Pharmacoeconomics of cisplatin-based chemoradiation in cervical cancer: a review
    Peter G Rose
    Department of Obstetrics and Gynecology, University Hospitals of Cleveland, Case Western Reserve University, Ohio, USA
    Expert Opin Pharmacother 3:1245-9. 2002
    ..In conclusion, cisplatin-based chemoradiation regimens increased mean survival at an acceptable cost per life-year gained in both the in-patient and out-patient settings...
  81. ncbi request reprint Stage IIB-IVA cancer of the cervix
    Peter G Rose
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio 44109, USA
    Cancer J 9:404-14. 2003
    ..However, these improvements, currently practiced in developed countries, must be implemented in underdeveloped countries which have the greatest burden of this disease...
  82. ncbi request reprint Progress in the management of gynecologic cancer: consensus summary statement
    Stephen A Cannistra
    Department of Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Brigham and Women s Hospital, Dana Farber Cancer Institute, and Massachusetts General Hospital, Boston, USA
    J Clin Oncol 21:129s-132s. 2003
  83. ncbi request reprint Role of pegylated liposomal doxorubicin in ovarian cancer
    J Tate Thigpen
    Division of Oncology, Department of Medicine, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA
    Gynecol Oncol 96:10-8. 2005
    ..The plethora of agents currently available present difficult choices for physicians. The present effort seeks to examine the role of one of these agents, pegylated liposomal doxorubicin...
  84. pmc Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study
    Lari Wenzel
    Center for Health Policy Research, Division of General Internal Medicine, College of Medicine, University of California, Irvine, USA
    J Clin Oncol 23:5605-12. 2005
    ....
  85. pmc Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study
    Martee L Hensley
    Memorial Sloan Kettering Cancer Center, Department of Medical Oncology, 1275 York Avenue, New York, NY 10021, USA
    Gynecol Oncol 109:323-8. 2008
    ..There is no standard second-line therapy. We determined activity of fixed-dose rate gemcitabine plus docetaxel as second-line treatment for metastatic uterine leiomyosarcoma...
  86. ncbi request reprint Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group
    Russell J Schilder
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Invest New Drugs 22:343-9. 2004
    ..This multi-center phase II trial was conducted by the Gynecologic Oncology Group to evaluate the activity and toxicity of irofulven in patients with previously treated adenocarcinoma of the endometrium...
  87. ncbi request reprint Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study
    Paula M Fracasso
    Division of Oncology, Washington University School of Medicine, St Louis, MO 63110, USA
    Gynecol Oncol 103:523-6. 2006
    ..A phase II study was conducted to determine the efficacy of oxaliplatin therapy in patients with advanced or recurrent endometrial cancer who had received one prior platinum therapy...
  88. ncbi request reprint The flower looks as good as its bud
    Peter G Rose
    Am J Obstet Gynecol 197:443-4. 2007
  89. ncbi request reprint Local relapse in patients treated for squamous cell vulvar carcinoma: incidence and prognostic value
    Peter G Rose
    Obstet Gynecol 101:1022; author reply 1023. 2003
  90. pmc Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial
    Martee L Hensley
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 109:329-34. 2008
    ..Fixed-dose rate gemcitabine plus docetaxel is active as second-line therapy for metastatic uterine leiomyosarcoma. We sought to determine the activity of this regimen as first-line treatment...
  91. ncbi request reprint Chemoradiation for locally advanced cervical cancer: does it help?
    Peter G Rose
    J Clin Oncol 20:891-3. 2002